Product Datasheet

TRAIL/TNFSF10 Antibody - BSA Free
NB500-220SS

Unit Size: 0.025 mg

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

www.novusbio.com technical@novusbio.com

Publications: 5

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NB500-220

Updated 9/9/2025 v.20.1

Earn rewards for product reviews and publications.
Submit a publication at www.novusbio.com/publications
Submit a review at www.novusbio.com/reviews/destination/NB500-220



NB500-220SS

TRAIL/TNFSF10 Antibody - BSA Free

Product Information	
Unit Size	0.025 mg
Concentration	1 mg/ml
Storage	Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.02% Sodium Azide
Isotype	IgG
Purity	Immunogen affinity purified
Buffer	PBS
Target Molecular Weight	36 kDa

Product Description	
Description	Novus Biologicals Rabbit TRAIL/TNFSF10 Antibody - BSA Free (NB500-220) is a polyclonal antibody validated for use in WB. Anti-TRAIL/TNFSF10 Antibody: Cited in 4 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
Host	Rabbit
Gene ID	8743
Gene Symbol	TNFSF10
Species	Human, Mouse
Reactivity Notes	Human, Mouse reactivity reported in scientific literature (PMID: 1914164).
Specificity/Sensitivity	Reacts with residues [SNTLSSPNSKNE] of the N terminus of the TRAIL protein.
Immunogen	residues [SNTLSSPNSKNE] of the N terminus of the TRAIL protein.

Product Application Details	
Applications	Western Blot
Recommended Dilutions	Western Blot 1:100-1:2000
Application Notes	Western blot- Use at 1:500 to 1:1,000 dilution. However, the investigator should determine the optimal dilution for a specific application such as immunohistochemistry The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Images



Effects of enolase 1, ubiquitin C, and iTS CM on the expression of tumor-promoting and tumor-suppressing genes. CM = conditioned medium, CN = control (no CM treatment), β-cat = β-catenin plasmids, siEno1 = Enolase 1 siRNA, siUbc = ubiquitin C siRNA, EO = EO771 mammary tumor cells. (A&B) Expression of MMP9, Runx2, Snail, p53, and TRAIL in response to enolase 1 and ubiquitin C in EO771 breast cancer cells. (C&D) Expression of MMP9, Runx2, Snail, p53, and TRAIL in response to β-catenin-overexpressing iTS CM impaired by siRNAs specific to enolase 1 and ubiquitin C. (E) Expression of PDL1 in EO771 mammary tumor cells in response to β-catenin-overexpressing iTS CM, enolase 1, and ubiquitin C. (F&G) Expression of MMP9, Runx2, Snail, p53, TRAIL, and caspase 3 in EO771 mammary tumor cells in response to β-catenin-overexpressing pre-treatment tumor cell-derived CM. (H) Low survival for cancer patients with a high transcript level of MMP9, Runx2, or Snail. (I) Proposed regulatory mechanism to inhibit tumor progression by iTS-CM. According to the mechanism, β-catenin-overexpressing iTS cells secrete ubiquitin C (Ubc), enolase 1 (Eno1), p53, and Trail. They suppress the progression of tumor cells by downregulating MMP9, Runx2, Snail, and PDL1, while upregulating cleaved-caspase 3. It should be noted that Eno1 interacts with CD44 and inhibits MMP9, Runx2, and Snail. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/34373756), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Effects of enolase 1, ubiquitin C, and iTS CM on the expression of tumor-promoting and tumor-suppressing genes. CM = conditioned medium, CN = control (no CM treatment), β-cat = β-catenin plasmids, siEno1 = Enolase 1 siRNA, siUbc = ubiquitin C siRNA, EO = EO771 mammary tumor cells. (A&B) Expression of MMP9, Runx2, Snail, p53, and TRAIL in response to enolase 1 and ubiquitin C in EO771 breast cancer cells. (C&D) Expression of MMP9, Runx2, Snail, p53, and TRAIL in response to β-catenin-overexpressing iTS CM impaired by siRNAs specific to enolase 1 and ubiquitin C. (E) Expression of PDL1 in EO771 mammary tumor cells in response to β-catenin-overexpressing iTS CM, enolase 1, and ubiquitin C. (F&G) Expression of MMP9, Runx2, Snail, p53, TRAIL, and caspase 3 in EO771 mammary tumor cells in response to β-catenin-overexpressing pre-treatment tumor cell-derived CM. (H) Low survival for cancer patients with a high transcript level of MMP9, Runx2, or Snail. (I) Proposed regulatory mechanism to inhibit tumor progression by iTS-CM. According to the mechanism, β-catenin-overexpressing iTS cells secrete ubiquitin C (Ubc), enolase 1 (Eno1), p53, and Trail. They suppress the progression of tumor cells by downregulating MMP9, Runx2, Snail, and PDL1, while upregulating cleaved-caspase 3. It should be noted that Eno1 interacts with CD44 and inhibits MMP9, Runx2, and Snail. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/34373756), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Publications

Haagsma J, Kolendowski B, Buensuceso A et al. Gain-of-function p53(R175H) blocks apoptosis in a precursor model of ovarian high-grade serous carcinoma Scientific Reports 2023-07-14 [PMID: 37452087] (Western Blot, Mouse)

Haagsma J, Kolendowski B, Buensuceso A et al. Gain-of-function p53 R175H blocks apoptosis in a precursor model of ovarian high-grade serous carcinoma Research Square 2023-03-24 (WB)

Feng Y, Liu S, Zha R et al. Prostate cancer-associated urinary proteomes differ before and after prostatectomy Therapeutic advances in medical oncology 2022-10-27 [PMID: 36324734] (WB, Human)

Feng Y, Liu S, Zha R, et al. Mechanical Loading-Driven Tumor Suppression Is Mediated by Lrp5-Dependent and Independent Mechanisms Cancers 2021-01-13 [PMID: 33450808] (WB, Mouse)

Herzer K, Hofmann TG, Teufel A et al. IFN-{alpha}-Induced Apoptosis in Hepatocellular Carcinoma Involves Promyelocytic Leukemia Protein TRAIL Independently of p53. Cancer Res;69(3):855-62. 2009-02-01 [PMID: 19141642] (WB, Mouse)

Novus Biologicals USA
10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada
21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd
19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information
www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NB500-220

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications